Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02). This innovative product is designed to accelerate artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery. The kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems.
Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Specifically designed for antibody drug discovery, the kit facilitates rapid expression and validation of VHH, scFv, Fab, and miniproteins. According to the company, XPressMAX™ achieves synthesis completion in just three hours with a success rate greater than 99% and supports complex disulfide bonding for native folding and bioactivity without additional enhancers.
By integrating with AI-powered screening platforms, the new offering empowers researchers to dramatically accelerate the identification and optimization of promising antibody candidates, reducing both development timelines and costs. Sino Biological has established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in three to four weeks to match AI's rapid iteration demands.
“Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.” Dr. Jie Zhang, Sino Biological’s General Manager, added, “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as three hours.”
Researchers can visit Sino Biological's product page for more information or request a free sample. The launch of XPressMAX™ represents a key development in the field of antibody discovery, particularly as AI continues to transform the pace of drug development. By providing a rapid and reliable protein expression system, Sino Biological is addressing a critical bottleneck in the high-throughput screening process, potentially enabling faster identification of therapeutic candidates for a range of diseases.
